IDO inhibitor

indoleamine 2,3-dioxygenase inhibitor · Genentech, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for IDO inhibitor, covering 2017-02-06 to 2024-03-27. Get the full timeline:

Most recent: Clinical Trial Update: Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors [Phase 1, Phase 2]